Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma

Схожие документы

• Safety, activity, and immune effects of lenalidomide and rituximab in untreated indolent lymphoma
  по: Fowler, Nathan H, et al.
  Опубликовано: (2014)
• Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
  по: Cheah, Chan Yoon, et al.
  Опубликовано: (2015)
• Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma
  по: Strati, Paolo, et al.
  Опубликовано: (2021)
• Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial
  по: Becnel, Melody R., et al.
  Опубликовано: (2019)
• Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma
  по: Oki, Yasuhiro, et al.
  Опубликовано: (2015)